A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-018-0387-x
Abstract: BackgroundPreclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to… read more here.
Keywords: vemurafenib patients; patients braf; braf v600; cohort ... See more keywords
Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9074
Abstract: 9074Background: BRAFV600 mutations occur in 1–2% of pts with NSCLC. We previously reported the efficacy of vemurafenib, a selective BRAFV600 inhibitor, in BRAF mutation-positive non-melanoma tumors (VE-BASKET study). We now present final data for the… read more here.
Keywords: vemurafenib patients; efficacy; brafv600; efficacy vemurafenib ... See more keywords